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101Safety and feasibility of adjunctive dexamethasone
infusion into the adventitia of the femoropopliteal
artery following endovascular revascularization
Christopher D. Owens, MD, MSc, Warren J. Gasper, MD, Joy P. Walker, MD, Hugh F. Alley, BA,
Michael S. Conte, MD, and S. Marlene Grenon, MD, San Francisco, Calif
Objective: Restenosis following endovascular treatment of the femoropopliteal segment is associated with the inﬂamma-
tory response produced in the artery wall at the time of the procedure. Although local drug delivery to the superﬁcial
femoral and popliteal arteries promises improved patency, data are currently limited. We hypothesized that improved
percutaneous delivery of an anti-inﬂammatory compound into the adventitia of the femoropopliteal at the time of
endovascular treatment would be safe, feasible, and decrease the inﬂammatory response.
Methods: This was a prospective, investigator-initiated, phase I, ﬁrst-in-man study testing the safety and feasibility of
percutaneous adventitial delivery of dexamethasone. Following successful intervention, an adventitial microinfusion
catheter was advanced over a 0.014-inch wire to the treated segment. Its microneedle (0.9 mm long 3 140-mm diam-
eter) was deployed into the adventitia to deliver dexamethasone (4 mg/mL) mixed with contrast agent (80:20 ratio),
providing ﬂuoroscopic visualization. The primary safety outcome measure was freedom from vessel dissection, throm-
bosis, or extravasation while the primary efﬁcacy outcome was duplex-determined binary restenosis deﬁned as a peak
systolic velocity ratio >2.5.
Results: Twenty patients with Rutherford clinical category 2-5 enrolled in this study. The mean age was 66, and 55% had
diabetes mellitus. Treated lesion length was 8.9 6 5.3 cm, and 50% were chronic total occlusions. Eighty percent of
treated lesions were in the distal superﬁcial femoral or popliteal arteries. All lesions were treated by balloon angioplasty
with provisional stenting (n[ 6) for suboptimal result. Three patients were treated with atherectomy as well. A mean of
1.6 6 1.1 mg (0.5 6 0.3 mL) of dexamethasone sodium phosphate was injected per centimeter of lesion length. In total,
a mean of 12.1 6 6.1 mg of dexamethasone was injected per patient. The mean number of injections required per lesion
was 3.0 6 1.3 cm, minimum one and maximum six injections. There was 100% technical success of drug delivery and no
procedural or drug-related adverse events. The mean Rutherford score decreased from 3.1 6 .7 (median, 3.0) preoper-
atively to .5 6 .7 at 6 months (median, 0.0; P < .00001). Over this same time interval, the index leg ankle-brachial index
increased from .68 6 .15 to .89 6 .19 (P [ .0003). The preoperative C-reactive protein in this study was 6.9 6 8.5
indicating severe baseline inﬂammation, which increased to 14.0 6 23.1 mg/L (103% increase) at 24 hours following the
procedure. However, this increase did not reach statistical signiﬁcance of P[ .14. Two patients met the primary efﬁcacy
end point of loss of primary patency by reoccluding their treated segment of the index lesion during the follow-up period.
Conclusions: Adventitial drug delivery via a microinfusion catheter is a safe and feasible alternative to intimal-based
methods for adjunctive treatment in the femoropopliteal segment. The 6-month preliminary results suggest peri-
vascular dexamethasone treatment may improve outcomes following angioplasty to the femoral and popliteal arteries, and
support further clinical investigation of this approach. (J Vasc Surg 2014;59:1016-24.)the Division of Vascular and Endovascular Surgery, University of
alifornia San Francisco Medical Center.
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6Balloon angioplasty superimposes an acute barotrau-
matic injury on a chronically inﬂamed artery, resulting in
the recruitment of neutrophils and macrophages into the
site of injury.1-3 These cells, in concert with intrinsic
vascular cells, participate in injury-induced stress responses,
which ultimately determine the fate of the revascularization
procedure.4,5 Vascular injury programs, mediated in part
by the coordinated activity of the inﬂammatory transcrip-
tion factors, nuclear factor kB and activated protein-1,
lead to the expression of a broad spectrum of inﬂammatory
proteins resulting in cellular proliferation, ﬁbrous protein
production, and remodeling of the vascular wall.6 The
magnitude of the inﬂammatory response has been linked
to subsequent restenosis in the femoropopliteal artery sug-
gesting that therapies, which mitigate the initial inﬂamma-
tory cascade, might improve patency.7
Glucocorticoids are powerful anti-inﬂammatory,
immune-suppressive, and anti-proliferative compounds
used to treat a variety of immune-mediated diseases.8
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approved by the Food and Drug Administration to treat
inﬂammatory conditions and is 25 times more potent
than hydrocortisone (cortisol) and has no mineralocorti-
coid crossover activity.8 While systemic delivery of
steroids9,10 following percutaneous coronary intervention
has had mixed results in part related to systemic side effects,
dexamethasone-coated stents have been more successful
demonstrating a reduction in binary restenosis and clinical
events.11-13 However, widespread adoption has been
limited given the older generation stent platforms and
the propensity for crystallization on the stent surface.
Endovascular adventitial delivery, through a micro-
infusion syringe is an attractive alternative for local drug
delivery because the drug can be injected directly into
the artery at the site of injury without the need for a perma-
nent implanted stent or partitioning from a balloon surface.
Adventitial delivery also establishes an outside-in concen-
tration gradient with the majority of the drug distributed
in the adventitia and media but relative sparing of endothe-
lial cells. Speciﬁcally targeting the adventitia is also of
interest as this outer vessel layer actively participates in
inﬂammatory cell recruitment, arterial remodeling, and
contribution of cells to neointima formation.1,14-16 Animal
studies have demonstrated that adventitial micro-infusion is
one of the most efﬁcient means of local drug delivery by
maximizing tissue concentration and minimizing plasma
levels and nontarget organ distribution of drug.17 Conse-
quently, pilot clinical trials have utilized this approach in
the coronary arteries to deliver bone marrow-derived
stem cells.18 However, this approach has not been utilized
in peripheral arteries. We hypothesized that percutaneous
delivery of dexamethasone with a microinfusion catheter
to the adventitia of symptomatic patients with peripheral
artery disease would be safe and feasible.
METHODS
Study design and patient population. This was
a ﬁrst-in-human study to test the safety and feasibility of
dexamethasone administration through a microinfusion
catheter (Bullfrog, Mercator MedSystems, Inc, San Lean-
dro, Calif) into the superﬁcial femoral and popliteal artery
(http://www.clinicaltrials.gov). Unique identiﬁer: NCT
01507558). The study design was a prospective, single-
center, investigator-initiated study that enrolled consecu-
tive patients who met eligibility requirements from the San
Francisco Veteran Affairs Medical Center. This study was
approved by the Committee for Human Research and the
University of California Clinical and Translational Science
Institute. Safety data and outcomes were monitored by
a Data Safety and Monitoring Committee that convened
on a quarterly basis or as needed.
The primary inclusion criteria were patients suffering
from moderate to severe disabling claudication, ischemic
rest pain, or minor tissue loss secondary to atherosclerotic
lower extremity occlusive disease with TransAtlantic
Inter-Society Consensus II A-D lesions of the superﬁcial
femoral artery (SFA) or popliteal arteries. The minimalreference vessel lumen diameter was required to be 3 to
6 mm, and the patient was required to have at least one
infrapopliteal runoff vessel. Exclusion criteria included
serum creatinine $2.5 mg/dL, prior revascularization of
the target limb, known allergy to contrast agents or dexa-
methasone, estimated life expectancy less than 1 year, or
other concurrent illness in which the investigators thought
would limit the patient’s ability to follow the schedule of
assessments.
Microinfusion catheter. The Bullfrog Micro-Infusion
Catheter (Mercator MedSystems, San Leandro, Calif) is
a rapid-exchange, wire-guided catheter with a balloon-
sheathed 0.9-mm-long, 35-gauge (140 mm diameter)
needle that delivers infusions to adventitial and perivascular
tissues (Fig 1). It is Food and Drug Administration 510(k)-
cleared for use in coronary and peripheral arteries. It is
advanced through a 6F sheath over a 0.014-inch wire and
can treat vessels from 3 to 6 mm in diameter (Fig 2). Three
radio-opaque markers on the catheter allow for proper
orientation of the needle. Using standard angioplasty
inﬂation equipment, the balloon is inﬂated exposing the
needle. When the balloon contacts the arterial wall opposite
the needle tip, contact pressure forces the needle through
the vessel wall and into the adventitia and perivascular
tissues. The contact pressure of the balloon against the
artery wall is limited to 2 atmospheres by a pressure release
valve, which prevents damage to the artery wall. A mixture
of infusate and contrast (4:1) is then delivered under ﬂuo-
roscopic guidance into the adventitia. A test injection of
0.1 mL is made to conﬁrm proper adventitial placement of
the microinfusion needle tip. If resistance is met, or the test
injection enters the blood stream, the balloon is deﬂated and
the injection is attempted in another location by moving the
catheter a few millimeters proximally or distally or rotating
the catheter a few degrees. Once adventitia placement is
conﬁrmed, the remainder of the infusate is delivered at a rate
of 1 mL/min. When the infusion is complete, the balloon is
deﬂated, sheathing the needle, and allowing the catheter to
be withdrawn (Fig 2). Injections were administered
approximately every 3 cm along the length of the treated
arterial segment. Because the drug:contrast admixture can
be visualized on both sides of the arterial wall, only one
ﬂuoroscopic view is necessary to conﬁrm circumferential
arterial coverage in the majority of cases.
Procedure. Patients not taking aspirin or clopidogrel
before study enrollment received 325 mg of aspirin
12 hours prior the procedure. Postprocedure, patients
were prescribed 81 mg/d of aspirin to be taken indeﬁnitely
and 75 mg/d of clopidogrel daily for 12 weeks. Vascular
access was accomplished by either the contralateral or ipsi-
lateral (anterograde) approach. Patients received a bolus of
5000 IU of heparin after insertion of the sheath in the
common femoral artery, and their activated clotting time
was kept above 250 seconds with additional heparin as
needed. In the case of chronic total occlusions, all lesions
were crossed subintimally with a glide wire and glide cath-
eter (Terumo, Somerset, NJ). After securing access across
the lesion with a guidewire, the target lesion was treated
Fig 1. The Bullfrog microinfusion catheter (A). Diffusion grading scale (B). A is supplied courtesy of Mercator
Medsystems (San Leandro, Calif).
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with balloon angioplasty. If a ﬂow-limiting dissection or
residual stenosis was determined to require a stent, the
protocol speciﬁed for treatment with dexamethasone prior
to stent placement. In all cases, the microinfusion catheter
was advanced to the treatment site following angioplasty to
deliver dexamethasone into the arterial adventitia.
Following the procedure, all patients were admitted for
a 23-hour observation period for access site, adverse event,
and revascularization monitoring. Prior to discharge, ankle-
brachial indexes (ABIs) and arterial duplex ultrasound
studies were performed in the vascular laboratory. Blood
was drawn at baseline and at 24 hours following the proce-
dure to assess the inﬂammatory response.
Dexamethasone dosing and rationale. The dosage
utilized in this protocol was an off-the-shelf concentra-
tion of dexamethasone sodium phosphate for injection
USP, 4 mg/mL, which is approved for reducing soft tissue
inﬂammation. Speciﬁcally, dexamethasone is indicated for
soft tissue injection of 0.4 to 6 mg to treat acute exacer-
bations in a variety of inﬂammatory conditions. Based on
these similar uses of the drug to treat localized inﬂamma-
tion, it was postulated that a similar dose (2-6 mg) should
be used to treat each 3 cm of lesion (0.7-2 mg/cm),
allowing for multiple infusions in the case of long lesions.
The 3-cm benchmark was chosen based on typical longi-
tudinal perivascular diffusion patterns in preclinical ex vivocadaveric femoral artery studies (unpublished data). The
dexamethasone sodium phosphate for injection USP,
which contains 4.0 mg dexamethasone phosphate per
milliliter, was mixed 80%:20% with an iso-osmolar iodin-
ated contrast medium (iodixanol 320 mg I/mL; GE
HealthCare, Cork, Ireland) resulting in a ﬁnal concentra-
tion of 3.2 mg dexamethasone phoshate and 60 to 74 mg
of iodine in each milliliter of solution. The ﬁnal dosing
target was, therefore, determined to be approximately
0.5 mL of the diluted drug per centimeter of lesion or
1.6 mg/cm.
The coinfusion of contrast medium with the drug
allowed the X-ray ﬂuoroscopic visualization required to
positively assess infusion success (Figs 2 and 3). All infu-
sions were graded based on the circumferential and longi-
tudinal distribution of the drug/contrast infusate and the
coverage of the target lesion (Fig 1). For example, an infu-
sion that was completely circumferential and extended
3 cm in either direction from the point of injection would
be considered a diffusion grade A. If infusions were only
partially circumferential or partially longitudinal, then
a grade of B was given and so on according to Fig 1.
Patient assessment and end point deﬁnitions. Med-
ical history was obtained before the procedure, including
concomitant medication use, Rutherford clinical cate-
gory, resting ABI, and laboratory results for baseline
C-reactive protein (CRP), serum creatinine, and lipids.
Fig 2. Endovascular treatment with adjunctive dexamethasone. This is a 49-year-old man with severe disabling
claudication and a 16-cm superﬁcial femoral artery (SFA) occlusion. Following securing access across the lesion with
a glide wire, the lesion was treated with balloon angioplasty. Following successful angioplasty, four 1.0-mL injections
were performed along the length of the lesion (only three shown). In the left panel, there is a discreet contrast blush
seen at each injection site. Note that the contrast appears circumferentially at each injection site. Three minutes later,
the drug-contrast admixture can be seen to have diffused longitudinally to fully cover the treated segment. The patient
is now 2 years from his index procedure and remains patent and complains of only mild claudication with heavy
exertion. He has an ankle-brachial index (ABI) of 1.09 and a peak systolic velocity ratio of less than 2.5.
Fig 3. Examples of typical dexamethasone-contrast diffusion patterns in patients treated in this study.
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index procedure and at each follow-up visit. Patients were
then reassessed with vascular history and physical exami-
nation, ABIs, and duplex arterial ultrasound examinationsat 1, 3, and 6 months. The primary safety end point was
freedom from death, vessel perforation, dissection,
thrombosis, or pseudoaneurysm formation within 30 days
following the procedure. The primary feasibility end
Table I. Baseline patient demographics and clinical
characteristics
Age, years 66 6 10
Male sex 20 (100)
Race
Caucasian 10 (50)
African American 7 (35)
Hispanic 2 (10)
Asian 1 (5)
Diabetes mellitus 11 (55)
Coronary artery disease 11 (55)
Hypertension 19 (95)
Hyperlipidemia 20 (100)
Body mass index, kg/m2 27.4 6 4.5
Creatinine, mg/dL 1.0 6 .34
CRP, mg/dL 6.9 6 8.5
Total cholesterol, mg/dL 149.1 6 37.5
Rutherford classiﬁcation 3 ¼ Moderate claudication
13 ¼ Severe claudication
3 ¼ Ischemic rest pain
1 ¼ Minor tissue loss
Index limb ABI .68 6 .15
ABI, Ankle-brachial index; CRP, C-reactive protein.
Continuous data are presented as mean 6 standard deviation and categoric
data as number (%).
Table II. Baseline lesion characteristics
SFA location Proximal SFA, 2 (10)
Mid-SFA, 2 (10)
Distal SFA, 8 (40)
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dexamethasone and contrast at the target lesion as
determined by the relationship of the ﬂuoroscopic blush
to the treatment segment. While not powered for an
efﬁcacy signal, the primary efﬁcacy end point was
a primary patency rate deﬁned as freedom from the
combined end points of target lesion revascularization,
occlusion, or >50% restenosis in the treated lesion.
Duplex ultrasonography was performed to assess reste-
nosis and >50% restenosis was deﬁned by a peak systolic
velocity ratio >2.5. Rates of target lesion revasculariza-
tion, death, and amputation end points were also
analyzed. Secondary end points were change in Ruth-
erford classiﬁcation and ABI from baseline to 6 months.
Inﬂammation as detected by plasma CRP has been
linked to restenosis following peripheral intervention. As
one of our intended goals was to reduce inﬂammation
following vascular intervention, serum CRP was measured
at baseline and 24 hours following the procedure.
Statistical analysis. This study was not powered for
clinical outcomes. Normally distributed continuous vari-
ables were expressed as mean and standard deviation and
were evaluated with the Student t-test or one-way analysis
of variance where appropriate. Proportions were evaluated
by the c2 test. Rutherford classiﬁcation and categorical
variables were assessed by the Kruskal-Wallis test. Safety
parameters were collected and assessed qualitatively or
summarized quantitatively by descriptive statistics. Statis-
tical signiﬁcance was set at the two-tailed .05 level.Popliteal, 8 (40)
Lesion length,a cm 8.9 6 5.3
Reference vessel diameter, mm 4.8 6 .1
Diameter stenosis (%) 78.5
Occlusion 10 (50)
% Occlusion 88 6 12
TASC II classiﬁcation A ¼ 5
B ¼ 11
C ¼ 2
D ¼ 2
Revascularization method PTA in 20 patients (100%)
þ atherectomy in three
patients (15%)
þ provisional stent in six
patients (30%)
PTA, Percutaneous transluminal angioplasty; SFA, superﬁcial femoral artery;
TASC, TransAtlantic Inter-Society Consensus.
Continuous data are presented as mean 6 standard deviation and categoric
data as number (%).
aNormal-to-normal lesion length as assessed by principal investigator.RESULTS
Patient proﬁle and lesion characteristics. Demo-
graphic and lesion characteristics are presented in Table I.
In brief, 20 male patients were enrolled in this study with
35% African American and 50% Caucasian. The mean age
of this cohort was 66.5 6 9.8 years, and 55% had diabetes
mellitus. Eighty percent of the patients had claudication,
the majority had a preoperative Rutherford score of 3
(65%), and the mean preoperative ABI index was .68 6
.15. Lesion characteristics treated in this study are pre-
sented in Table II. The mean lesion length was 8.9 6
5.3 cm (2.3-25.2 cm), and 50% of treated lesions were
chronic total occlusions. Eighty percent of lesions were
located in the distal SFA and/or popliteal artery. The mean
reference vessel diameter was 4.8 6 .1 mm. Six patients
(30%) required the placement of a self-expanding stent
because of residual stenosis or ﬂow-limiting dissection
following balloon angioplasty. The lesion characteristics of
the patients who received stents including percentage
occlusions or lesion length were not different than those
who were not stented.
Safety of adventitial delivery of dexamethasone. There
were no device-related adverse events in this study.
There were no amputations or deaths at 30 days or during
follow-up. There were no dissections, pseudoaneurysm
formation, or 30-day thrombosis. There was one case of
hyperglycemia following dexamethasone treatment ina long-standing diabetic patient who did not receive his
hypoglycemic medications.
Technical considerations and feasibility of femo-
ropopliteal adventitial delivery. In all cases, dexametha-
sone was able to be delivered to the adventitia of the
target lesion. The mean number of injections required
per lesion was 3.0 6 1.3 cm, minimum one and maximum
six injections. Each injection was graded on an ordinal
descriptive scale as depicted in Fig 1. In 19 out of 20
subjects, there was complete circumferential coverage of
Fig 4. The mean ankle-brachial index (ABI) is signiﬁcantly
improved from baseline across all time points postprocedure.
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the infusion (grade ¼ A). In one patient, there was only
partial coverage noted by contrast distribution (grade ¼ B).
The mean volume injected was 3.8 6 1.9 mL, which
contained a mean of 12.1 6 6.1 mg of dexamethasone
sodium phosphate and .80 6 .4 mL of contrast. This
equated to a mean of 1.6 6 1.1 mg of dexamethasone
sodium phosphate per centimeter of lesion length. The
minimal dose was 3.2 mg, and the maximal dose a patient
received was 24 mg of dexamethasone sodium phosphate.
Accordingly, there was a positive linear correlation between
the amount of dexamethasone received and length of
lesion treated (R2 ¼ .27; P ¼ .019).
Inﬂammatory response. The postintervention im-
mune response following femoropopliteal intervention has
been shown to be independently associated with subse-
quent restenosis. The preoperative CRP for subjects in
this study was 6.9 6 8.5 indicating severe baseline inﬂam-
mation, which increased to 14.0 6 23.1 mg/L (103%
increase) at 24 hours following the procedure indicating
that there was an inﬂammatory response following periph-
eral intervention. However, this increase did not reach
statistical signiﬁcance (P ¼ .14).
Effectiveness. Two patients in this study reached the
primary end point of loss of primary patency by duplex
ultrasound-determined binary restenosis by 6 months.
The ﬁrst, a 77-year-old man who had an 11.9 cm chronic
total occlusion involving the distal SFA extending into the
popliteal artery treated with balloon angioplasty and a 7- by
100-mm Everﬂex stent (Covidien, Plymouth Minn) was
found to have reoccluded his lesion at 172 days following
the procedure. The second patient is a 63-year-old man
that had a 10-cm popliteal artery occlusion, which was
treated by angioplasty and was found to have reoccluded
182 days following his procedure. The mean preoperative
Rutherford score decreased from 3.1 6 .71 (median, 3.0)
preoperatively to .5 6 .70 (median, 0) at 6 months; P <
.00001. Over this same time interval, the preoperative
index leg ABI increased from .68 6 .15 (range, .22-.89) to
.89 6 .19 (range, .49-1.2; P ¼ .0003; Fig 4).
DISCUSSION
This ﬁrst-in-human study establishes the safety and
feasibility of adventitial delivery of dexamethasone into
the femoropopliteal artery to augment patency after thera-
peutic interventions. An additional novel feature of this
methodology is that the drug-contrast admixture can be
seen “staining” the area of interest thereby providing visual
conﬁrmation of drug delivery. Because the Bullfrog cath-
eter is a microinfusion device, the dose applied can be
titrated to deliver a desired concentration of drug and
scaled to the length of artery treated rather than relying
on passive elution from a ﬁxed-length stent or balloon
surface. Therefore, this represents a signiﬁcant departure
from intimal-based drug delivery methods and is the ﬁrst
application of this technology to the peripheral vasculature.
Additional novelty is found in the ability to percutane-
ously deliver the anti-inﬂammatory drug dexamethasone tothe adventitia, hence establishing a reverse concentration
gradient with maximal drug concentration located in the
adventitia and outer media with relatively sparing of the
endothelial cell layer. This outside-in approach of drug
delivery speciﬁcally targets the adventitia, which has been
shown to be an active participant in vascular remodeling
after angioplasty.1,2 Once thought to be a passive layer
within the arterial wall, the tunica adventitia is now known
to be extremely metabolically active and capable of regu-
lating vascular homeostasis.15 Following vascular injury,
resident adventitial ﬁbroblasts undergo transformation
into myoﬁbroblasts, which have been shown to contribute
to neointimal growth and vessel contraction. In porcine
models of balloon angioplasty, injections with 5-bromo-
2-deoxyuridine have identiﬁed the majority of the ﬁrst
wave of proliferating cells to be located in the adventitia
as early as 2 days following injury.19,20 Further, Shi et al
demonstrated that adventitial myoﬁbroblasts both
contribute to synthesis of extracellular matrix including
collagen and migrate into the developing neointima
following balloon injury.21,22 Finally, utilizing in vivo
reporter gene transfer studies into adventitial cells, Siow
et al demonstrated adventitial myoﬁbroblast migration
into the media and neointima following balloon injury.16
Collectively, these studies provide important biological
rationale supporting the targeting the adventitia to reduce
the rate of restenosis.
The hypothesis that restenosis principally occurs in
those whose inﬂammation associated with vascular healing
is excessive or is not appropriately turned off is intriguing
but has not been clinically conﬁrmed. However, it has
been known for over 25 years that inﬂammation is involved
in nearly every step in restenosis and that the adventitia
harbors a rich array of inﬂammatory cells including macro-
phages, dendritic cells, lymphocytes, neutrophils and mast
cells.23 Within hours following vascular wall injury, addi-
tional inﬂammatory cells home to the site of injury and
liberate cytokines, growth factors and reactive oxygen
species that contribute to the proliferation of smooth
JOURNAL OF VASCULAR SURGERY
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evidence that the magnitude of inﬂammation at baseline
as well as the spike in inﬂammation following vascular
intervention is correlated with the subsequent restenosis.25
In this regard, Schillinger et al demonstrated that plasma
CRP increased in patients without restenosis by 113%,
whereas CRP increased by 155% at 24 hours in patients
who subsequently developed restenosis of their treated
lesions.25 Accordingly, therapies speciﬁcally targeting
inﬂammation may inhibit or dampen the proliferative
response.
Glucocorticoids are ideal candidates to repress
angioplasty-induced immune response programs by inhib-
iting inﬂammatory transcription factors, nuclear factor
kB and activated protein-1, and their downstream me-
diators.6,26 Preclinical studies have demonstrated that
dexamethasone downregulates monocyte chemoattractant
protein-1, tumor necrosis factor a and interleukin 1b in
nano- and micromolar concentrations in vascular smooth
muscle cells.27,28 In the speciﬁc context of neointimal
hyperplasia and vascular restenosis, dexamethasone has
been shown to inhibit the proliferation and migration of
smooth muscle and inﬂammatory cells as well as adventitial
myoﬁbroblasts through effects on thymidine kinase, matrix
metalloproteinases, and retinoblastoma protein.29-31 Clin-
cally, dexamethasone has been shown to reduce soluble
inﬂammatory proteins following vascular intervention.
For example, patients with unstable angina treated with
dexamethasone-eluting stents had lower plasma concentra-
tions of CRP, intercellular adhesion molecule-1, and
vascular cell adhesion molecule-1 postintervention com-
pared with patients treated with a bare metal stent.32,33
Dexamethasone induces the anti-inﬂammatory proteins
annexin 1 and mitogen-activated kinase phosphatase 1
while repressing the transcription of proinﬂammatory
molecules such as cyclooxygenase 2.34 Dexamethasone
also markedly inhibits the production of reactive oxygen
species by mononuclear cells and polymorphonuclear leu-
kocytes in vivo. Dexamethasone increases the immune-
modulatory cytokine interleukin 10 which is known to
inhibit the proinﬂammatory TH1 cells.35 Finally, by deliv-
ering an anti-inﬂammatory drug shown to improve endo-
thelial cell migration, the need for dual antiplatelet
therapy required after a limus or taxol-eluting stent or
balloon may not be necessary.
Limitations. This was a pilot safety and feasibility
study with short follow-up of a heterogeneous group of
symptomatic patients with peripheral artery disease. The
lesions were distributed in the SFA and popliteal artery and
treated with a variety of interventions including angioplasty
and atherectomy. Provisional stenting was applied when
necessary. The intent of the study was to determine the
safety and feasibility of adventitial steroid delivery in the
periphery. Nevertheless, this was an extremely morbid
cohort reﬂected by a mean CRP >6 mg/L with chal-
lenging lesion characteristics. The treated lesion was over
8 cm, and 50% of lesions were chronic total occlusions.
Further, 80% of treated lesions included the distal SFA andpopliteal arteries, which have traditionally been considered
no-stent zones. No core facility was employed to either
adjudicate duplex ultrasound or angiographic results in this
study. Although the 6-month patency results were
considered to be excellent, no conclusions about efﬁcacy
can be drawn from a pilot trial design.
CONCLUSIONS
This pilot study establishes that adventitial delivery of
dexamethasone using a microinfusion catheter following
femoropopliteal intervention is safe and feasible. This
method of local drug delivery represents an alternative to
intimal-based delivery platforms and may have unique
advantages. Further study is required to determine the efﬁ-
cacy of this approach to improve vessel patency.
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and feasibility trial. As such, there is not much data to discuss in
this paper. The 20 patients treated did reasonably well, but without
a control group, it is hard to say whether or not this technology
was helpful. But, it is clear that localized drug delivery is the
next big thing in endovascular therapy. Whether this will involve
drug elution or, as in this case, localized drug injection, whether
this will involve treating the intima, media, or adventitia, what
the proper medication or perhaps gene product will be remains
to be seen, but this area is moving forward at immense speed.
My questions are primarily technical:
1. Are there vessel characteristics or issues, such as calciﬁcation,
thrombus, or subintimal wire passage, that limit the use of
this technology?2. Why is there only one needle in the catheter? While it seems to
be able to circumferentially deliver the drug in most cases, is
there a technical reason that the multiple needles could not
be placed helically on the balloon to deliver the drug more
uniformly?
3. Since this does treat a different vessel layer than the drug
eluting balloons, do you see this as complementary or as
competitive technology?
4. This balloon was proposed for use in renal denervation. Is this
still being investigated?
I look forward to seeing your ongoing progress in this work.
Dr Christopher D. Owens. I would like to thank Dr Landry
for his comments on our paper. He is correct that this is only
a safety and feasibility trial and was not designed or powered to
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1024 Owens et al April 2014assess efﬁcacy. This was a ﬁrst in-human study, and we had no prior
knowledge of whether therapeutic agents could be delivered to
peripheral arteries in this manner. In this sense, it was entirely
proof of concept.
These were all pretty challenging cases. There were 50%
occlusions, and the average lesion was about 9 cm. In addition,
most of the lesions involved the popliteal artery, which has been
a problematic area for stents. We were able to deliver dexametha-
sone to the perivascular tissue in all cases. We did not choose to
treat anyone with fresh thrombus. I think that circumferential
calciﬁcation would be a limitation of the technology going
forward, because it is simply a physical barrier for needle or drug
penetration. Circumferential calciﬁcation is problematic forany drug delivery platform. However, we found that if you can
get the needle through the vessel wall, then drugs will diffuse cir-
cumferentially, 360 degrees, around the vessel in most cases
despite partial calciﬁcation.
Regarding whether this is complementary or competitive to
intimal-based drug delivery platforms such as balloons or stents,
I believe this to be complementary. Further, we are targeting
inﬂammation rather than proliferation.
Finally, we have presented our preclinical renal denervation studies
at the Society for Vascular Surgery meeting, whereby we used the bull-
frog catheter to deliver guanethidine to the adventitia of renal arteries
to chemically destroy the sympathetic nerve ﬁbers. Regulatory work is
ongoing so that we can move into early phase human studies.
